Loading…
Personal Care Products Safety Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Personal Care Products Safety Act This bill amends the Federal Food, Drug, and Cosmetic Act to require cosmetics companies to register their facilities with the Food and Drug Administration (FDA) and to submit to the FDA cosmetic ingredient statements that include the amounts of a cosmetic's ingredients. Companies must pay a facility registration fee based on their annual gross sales of cosmetics. The collected fees can only be used for cosmetic safety activities. If the FDA determines that a cosmetic has a reasonable probability of causing serious adverse health consequences, it may prohibit the cosmetic's distribution by suspending the cosmetic ingredient statement. If other cosmetics from the same facility may be affected, the FDA may prohibit distribution from the facility by suspending the facility's registration. The FDA must review the safety of at least five cosmetic ingredients each year, and it may establish conditions for safe use of an ingredient, including a limit on the amount of the ingredient or a requirement for a warning label. A cosmetic cannot be sold if it contains an ingredient that is not safe, not safe under the recommended conditions of use, or not safe in the amount present in the cosmetic. Cosmetics companies are required to report to the FDA any serious adverse health event associated with their cosmetics. The FDA must: develop and implement cosmetic manufacturing standards that are consistent with existing national and international standards, be allowed to inspect a company's cosmetic safety records, recall a cosmetic that is likely to cause serious adverse health consequences, and encourage cosmetic safety testing practices that minimize the use of animals.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2918-2919)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2018 · fourth_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018; H.R. 6022, Accurate Labels Act; H.R. 6653, IMAGINE Act; H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3341, IMAGINE Act; S. 3381, PFAS Accountability Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. 3671 A bill to require the Administrator of the Environmental Protection Agency to revise certain ethylene oxide emissions standards under the Clean Air Act, and for other purposes; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
Client expense: $1,940,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · third_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018 H.R. 6022, Accurate Labels Act H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
2018 · fourth_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018; H.R. 6022, Accurate Labels Act; H.R. 6653, IMAGINE Act; H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3341, IMAGINE Act; S. 3381, PFAS Accountability Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. 3671 A bill to require the Administrator of the Environmental Protection Agency to revise certain ethylene oxide emissions standards under the Clean Air Act, and for other purposes; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
2018 · third_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018 H.R. 6022, Accurate Labels Act H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
2018 · second_quarter · Chemicals/Chemical Industry
H.R. 5, Regulatory Accountability Act of 2017; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 45, Regulatory Accountability Act of 2017; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 4170, Disclosing Foreign Influence Act; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018 H.R. 6022, Accurate Labels Act H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 3019, Accurate Labels Act S. Res. 301 S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
| Democratic |
| DE |
| Jeanne Shaheen | Democratic | NH |
| Kamala D. Harris | Democratic | CA |
| Kirsten E. Gillibrand | Democratic | NY |
| Margaret Wood Hassan | Democratic | NH |
| Mazie K. Hirono | Democratic | HI |
| Michael F. Bennet | Democratic | CO |
| Patrick J. Leahy | Democratic | VT |
| Richard Blumenthal | Democratic | CT |
| Sheldon Whitehouse | Democratic | RI |
| Shelley Moore Capito | Republican | WV |
| Susan M. Collins | Republican | ME |
| Tom Udall | Democratic | NM |
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Client expense: $1,940,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Client expense: $3,600,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · second_quarter · Health Issues
Cosmetic safety legislation including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act.
Client expense: $290,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of
2018 · fourth_quarter · Health Issues
Cosmetic safety legislation, including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act. Opioid legislation affecting the industry, including: H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271).
Client expense: $250,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · second_quarter · Health Issues
Cosmetic safety legislation including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act.
Client expense: $260,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE, State, Dept of (DOS), Treasury, Dept of
2018 · fourth_quarter · Pharmacy
- OTC drugs, devices and cosmetics - OTC monograph reform - S.1113, Personal Care Products Safety Act - S.2315/H.R.5333, Over-the-Counter Drug Safety, Innovation, and Reform Act
Client expense: $693,588 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2018 · fourth_quarter · Consumer Issues/Safety/Products
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, S. 2003, FDA Cosmetic Safety and Modernization Act; and Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft).
Client expense: Not reported · Firm income: $120,000
Government targets: SENATE
2018 · fourth_quarter · Environment/Superfund
Clean Air Act, S. 1113- the Personal Care Products Safety Act, environmental impact on child development,antibiotic resistance, implementation of The Frank R. Lautenberg Chemical Safety for the 21st Century Act.
Client expense: $30,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)
2018 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 575, Cosmetic Modernization Amendments of 2017; S. 1113, Personal Care Products Safety Act; S. 2003, FDA Cosmetic Safety and Modernization Act; Modernization of Cosmetics Regulation Act of 2018 (S. HELP Committee discussion draft); Issues related to sunscreen regulations
Client expense: $370,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2018 · fourth_quarter · Consumer Issues/Safety/Products
S. 1113 Personal Care Product's Safety Act -- all areas of the bill
Client expense: $620,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
S. 1113 Personal Care Product's Safety Act -- all areas of the bill
Client expense: $440,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
Cosmetics Legislation: S.1113 (Feinstein) - Personal Care Products Safety Act
Client expense: Not reported · Firm income: $100,000
Government targets: SENATE, White House Office
2018 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 906 (Furthering Asbestos Claims Transparency Act); amends title 11 of the United States Code to require the public disclosure by trusts established under section 524(g) of such title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos. H.R. 1563 (Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2017); amends the Public Health Service Act to provide for the establishment of a mesothelioma patient registry. H.R. 575 (Cosmetic Modernization Amendments of 2017); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. S. 1113 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 832 (Arbitration Transparency Act); amends title 9 of the United States Code to require that arbitration proceedings in certain disputes involving consumer financial products and services be open to the public. S. 542 (Safety Over Arbitration Act of 2017); amends title 9, United States Code, with respect to arbitration where the claim or controversy alleges facts relevant to a hazard to public health or safety. S. 552/H.R. 1414 (Justice for Victims of Fraud Act); amends the Truth in Lending Act and the Electronic Fund Transfer Act to provide justice to victims of fraud. S. 550/H.R. 1396 (Restoring Statutory Rights Act); invalidates arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution. S. 646/H.R. 2631 (Justice for Servicemembers and Veterans Act); amends title 38, United States Code, to improve the enforcement of employment and reemployment rights of members of the uniformed services, to amend the Servicemembers Civil Relief Act to improve the protection of members of the uniformed services. S. 647 (Mandatory Arbitration Transparency Act); amends title 9, United States Code, with respect to arbitration. S. 537/H.R. 1374 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in employment, consumer, antitrust, or civil rights disputes. S. 2203/H.R. 4734/H.R. 4570 (Ending Forced Arbitration of Sexual Harassment Act of 2017); prohibits a pre-dispute arbitration agreement from being valid or enforceable if it requires arbitration of a sex discrimination dispute. H.R. 3857 (PASS Act of 2017); amend the Securities Exchange Act of 1934 to lower standards of conduct for brokers and dealers that are in the best interest of their retail customers. S. 534/H.R. 1973 (Protecting Young Victims from Sexual Abuse Act of 2017); prevents the sexual abuse of minors and amateur athletes by requiring the prompt reporting of sexual abuse to law enforcement authorities S. 2564, (PROTECT Asbestos Victims Act of 2018); restricts claims against asbestos trusts and provides for criminal penalties for fraudulent claims. S. 1112, (Maternal Health Accountability Act of 2017); retricts the use of information reviewed by the maternal mortality review committee. Infomration is considered confidential and not subject to dioscvery at a civil trial. S. 2852 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018); regarding immunity provisions, and additional variations of the bill including: H.R. 7328 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018) and H.R. 6378 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018). H.R. 6022/ S. 3019 (Accurate Labels Act); regarding the broad preemption of state and local labeling laws for consumer products. H.R. 6903 (Safe Cosmetics and Personal Care Products Act of 2018); amends current law to ensure the safety of cosmetics and personal care products. H.R. 919 (Blitz Gas Can bill). H.R. 3850 (Made in America Act of 2017); directs the FTC to establish labels that may be used as a voluntary means of indicating to consumers the extent to which products are of US origin; more specifically about the FTC enforcement authority. General issues pertaining to Asbestos Bankruptcy Trusts. Cosmetic Regulation and Safety and realted preemption issues in Murray Alexander draft bill. General lobbying with regard to the Education Departments borrower defenses rule. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. General lobbying with regard to pesticide regulations. General lobbying with regard to amending Telephone Consumer Protection Act liability. General lobbying with regard to attorney advertising issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to TSCA implementation. General lobbying with regard to asbestos in talc and talc generally. General lobbying with regard to nursing home arbitration. General lobbying with regard to issues relating to PFOA.
Client expense: $1,300,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2018 · fourth_quarter · Health Issues
Administrative and legislative monitoring and outreach on issues related to cosmetic regulation and reform. H.R. 575, Cosmetic Modernization Amendments of 2017. S. 1113, Personal Care Products Safety Act. S. 2003, FDA Cosmetic Safety and Modernization Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety - HR 6, "SUPPORT for Patients and Communities Act", regarding all provisions. - S. 2315, "Over-the-Counter Drug Safety, Innovation, and Reform Act", regarding all provisions. - HR 5333 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", regarding all provisions. - Issues related to antimicrobial resistance - Issues related to regulations on medication product packaging - H.R. 6294, " Re-Valuing Anti-Microbial Products Act of 2018", regarding all provisions - H.R. 1318, "Preventing Maternal Deaths Act of 2018", regarding all provisions
Client expense: $2,340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
2018 · fourth_quarter · Consumer Issues/Safety/Products
FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber security and digital privacy proposals. S. 1113 - Personal Care Products Safety Act. S. 2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2018 · fourth_quarter · Consumer Issues/Safety/Products
S. 1113, The Personal Care Products Safety Act
Client expense: Not reported · Firm income: $20,000
Government targets: SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
Legislation relating to Cosmetics Reform (chemical safety, cosmetic ingredient safety, and disclosure of fragrance ingredients in consumer products). HR 575; S 1113; S 2003; HR 4964; HR 6903, all provisions. Formation of Congressional Fragrance Caucus.
Client expense: $80,000 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products. Implementation of the 21st Century Cures Act (P.L.114-255). S.1113, Personal Care Products Safety Act. S.2003, FDA Cosmetic Safety and Modernization Act. S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act. H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018. H.R.6, SUPPORT for Patients and Communities Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Chemicals/Chemical Industry
HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Health Issues
HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Environment/Superfund
HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Client expense: Not reported · Firm income: $10,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018; H.R. 6022, Accurate Labels Act; H.R. 6653, IMAGINE Act; H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3341, IMAGINE Act; S. 3381, PFAS Accountability Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. 3671 A bill to require the Administrator of the Environmental Protection Agency to revise certain ethylene oxide emissions standards under the Clean Air Act, and for other purposes; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
Client expense: $1,940,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · fourth_quarter · Health Issues
Cosmetic safety legislation, including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act. Opioid legislation affecting the industry, including: H.R.6, SUPPORT for Patients and Communities Act (P.L.115-271).
Client expense: $230,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
2018 · fourth_quarter · Health Issues
Cosmetic safety legislation including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act. H.R.6 SUPPORT for Patients and Communities Act (P.L.115-271)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
H.R. 575 - Cosmetic Modernization Amendments of 2017 S. 1113 - Personal Care Products Safety Act. Issues related to sunscreen regulations.
Client expense: Not reported · Firm income: $80,000
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2018 · fourth_quarter · Health Issues
OTC drugs and cosmetics reform, including Personal Care Products Safety Act (S. 1113), FDA Cosmetic Safety and Modernization Act (S. 2003), Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft), Over-the-Counter Drug Safety, Innovation and Reform Act (S. 2315), and Over-the-Counter Monograph Safety, Innovation and Reform Act of 2018 (H.R. 5333)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Consumer Issues/Safety/Products
Modernization of Cosmetic Regulations H.R. 575 - Cosmetic Modernization Amendments of 2017 S. 1113 - Personal Care Products Safety Act Safety of Cosmetic/Personal Care/Household Cleaning Products & Ingredients FDA Regulation of OTC Drugs OTC Drug Monograph Reform - H.R. 5333 & S. 2315 Ingredient Disclosure - Cleaning Products
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Consumer Issues/Safety/Products
H.R. 906 (Furthering Asbestos Claims Transparency Act); amends title 11 of the United States Code to require the public disclosure by trusts established under section 524(g) of such title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos. H.R. 1563 (Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2017); amends the Public Health Service Act to provide for the establishment of a mesothelioma patient registry. H.R. 575 (Cosmetic Modernization Amendments of 2017); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. S. 1113 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 832 (Arbitration Transparency Act); amends title 9 of the United States Code to require that arbitration proceedings in certain disputes involving consumer financial products and services be open to the public. S. 542 (Safety Over Arbitration Act of 2017); amends title 9, United States Code, with respect to arbitration where the claim or controversy alleges facts relevant to a hazard to public health or safety. S. 552/H.R. 1414 (Justice for Victims of Fraud Act); amends the Truth in Lending Act and the Electronic Fund Transfer Act to provide justice to victims of fraud. S. 550/H.R. 1396 (Restoring Statutory Rights Act); invalidates arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution. S. 646/H.R. 2631 (Justice for Servicemembers and Veterans Act); amends title 38, United States Code, to improve the enforcement of employment and reemployment rights of members of the uniformed services, to amend the Servicemembers Civil Relief Act to improve the protection of members of the uniformed services. S. 647 (Mandatory Arbitration Transparency Act); amends title 9, United States Code, with respect to arbitration. S. 537/H.R. 1374 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in employment, consumer, antitrust, or civil rights disputes. S. 2203/H.R. 4734/H.R. 4570 (Ending Forced Arbitration of Sexual Harassment Act of 2017); prohibits a pre-dispute arbitration agreement from being valid or enforceable if it requires arbitration of a sex discrimination dispute. H.R. 3857 (PASS Act of 2017); amend the Securities Exchange Act of 1934 to lower standards of conduct for brokers and dealers that are in the best interest of their retail customers. S. 534/H.R. 1973 (Protecting Young Victims from Sexual Abuse Act of 2017); prevents the sexual abuse of minors and amateur athletes by requiring the prompt reporting of sexual abuse to law enforcement authorities S. 2564, (PROTECT Asbestos Victims Act of 2018); restricts claims against asbestos trusts and provides for criminal penalties for fraudulent claims. S. 1112, (Maternal Health Accountability Act of 2017); retricts the use of information reviewed by the maternal mortality review committee. Infomration is considered confidential and not subject to dioscvery at a civil trial. S. 2852 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018); regarding immunity provisions. H.R. 6022/ S. 3019 (Accurate Labels Act); regarding the broad preemption of state and local labeling laws for consumer products. Cosmetic Regulation and Safety and realted preemption issues in Murray Alexander draft bill. General lobbying with regard to the Education Departments borrower defenses rule. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. General lobbying with regard to pesticide regulations. General lobbying with regard to amending Telephone Consumer Protection Act liability. General lobbying with regard to attorney advertising issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to TSCA implementation.
Client expense: $1,430,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Environment/Superfund
Clean Air Act, S. 1113- the Personal Care Products Safety Act, environmental impact on child development,antibiotic resistance, implementation of The Frank R. Lautenberg Chemical Safety for the 21st Century Act.
Client expense: $20,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Postal Regulatory Commission, SENATE, Treasury, Dept of, U.S. Postal Service (USPS)
2018 · third_quarter · Consumer Issues/Safety/Products
Consumer product safety issues related to potential amendments to the FDA's regulatory authorities over cosmetics, including S. 1113, Personal Care Products Safety Act, S. 2003, FDA Cosmetic Safety and Modernization Act; and Modernization of Cosmetics Regulation Act of 2018 (Senate HELP Committee Discussion Draft).
Client expense: Not reported · Firm income: $140,000
Government targets: SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
S. 1113 Personal Care Product's Safety Act -- all areas of the bill
Client expense: $360,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
S.1113, "Personal Care Products Safety Act", issues relating to the regulation of cosmetics.
Client expense: $600,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Cosmetic safety legislation, including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act. Opioid legislation affecting the industry, including: H.R.6, SUPPORT for Patients and Communities Act, H.R.5228, SCREEN Act, H.R.5752, Stop Illicit Drug Importation Act of 2018, and S.2680, Opioid Crisis Response Act of 2018.
Client expense: $240,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), Treasury, Dept of
2018 · third_quarter · Pharmacy
- OTC drugs, devices and cosmetics - OTC monograph reform - S.1113, Personal Care Products Safety Act - S.2315/H.R.5333, Over-the-Counter Drug Safety, Innovation, and Reform Act
Client expense: $810,232 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2018 · third_quarter · Consumer Issues/Safety/Products
H.R. 906 (Furthering Asbestos Claims Transparency Act); amends title 11 of the United States Code to require the public disclosure by trusts established under section 524(g) of such title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos. H.R. 1563 (Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2017); amends the Public Health Service Act to provide for the establishment of a mesothelioma patient registry. H.R. 575 (Cosmetic Modernization Amendments of 2017); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. S. 1113 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 832 (Arbitration Transparency Act); amends title 9 of the United States Code to require that arbitration proceedings in certain disputes involving consumer financial products and services be open to the public. S. 542 (Safety Over Arbitration Act of 2017); amends title 9, United States Code, with respect to arbitration where the claim or controversy alleges facts relevant to a hazard to public health or safety. S. 552/H.R. 1414 (Justice for Victims of Fraud Act); amends the Truth in Lending Act and the Electronic Fund Transfer Act to provide justice to victims of fraud. S. 550/H.R. 1396 (Restoring Statutory Rights Act); invalidates arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution. S. 646/H.R. 2631 (Justice for Servicemembers and Veterans Act); amends title 38, United States Code, to improve the enforcement of employment and reemployment rights of members of the uniformed services, to amend the Servicemembers Civil Relief Act to improve the protection of members of the uniformed services. S. 647 (Mandatory Arbitration Transparency Act); amends title 9, United States Code, with respect to arbitration. S. 537/H.R. 1374 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in employment, consumer, antitrust, or civil rights disputes. S. 2203/H.R. 4734/H.R. 4570 (Ending Forced Arbitration of Sexual Harassment Act of 2017); prohibits a pre-dispute arbitration agreement from being valid or enforceable if it requires arbitration of a sex discrimination dispute. H.R. 3857 (PASS Act of 2017); amend the Securities Exchange Act of 1934 to lower standards of conduct for brokers and dealers that are in the best interest of their retail customers. S. 534/H.R. 1973 (Protecting Young Victims from Sexual Abuse Act of 2017); prevents the sexual abuse of minors and amateur athletes by requiring the prompt reporting of sexual abuse to law enforcement authorities S. 2564, (PROTECT Asbestos Victims Act of 2018); restricts claims against asbestos trusts and provides for criminal penalties for fraudulent claims. S. 1112, (Maternal Health Accountability Act of 2017); retricts the use of information reviewed by the maternal mortality review committee. Infomration is considered confidential and not subject to dioscvery at a civil trial. S. 2852 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018); regarding immunity provisions. H.R. 6022/ S. 3019 (Accurate Labels Act); regarding the broad preemption of state and local labeling laws for consumer products. H.R. 6903 (Safe Cosmetics and Personal Care Products Act of 2018); amends current law to ensure the safety of cosmetics and personal care products. H.R. 919 (Blitz Gas Can bill). General issues pertaining to Asbestos Bankruptcy Trusts. Cosmetic Regulation and Safety and realted preemption issues in Murray Alexander draft bill. General lobbying with regard to the Education Departments borrower defenses rule. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. General lobbying with regard to pesticide regulations. General lobbying with regard to amending Telephone Consumer Protection Act liability. General lobbying with regard to attorney advertising issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to TSCA implementation.
Client expense: $1,510,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC)
2018 · third_quarter · Consumer Issues/Safety/Products
Cosmetics Legislation: S.1113 (Feinstein) - Personal Care Products Safety Act
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
Advocate for S. 1113, the Personal Care Products Safety Act; discuss the importance of modernizing the Federal Food, Drug, and Cosmetics Act; monitor for additional efforts to update and modernize the Federal Food, Drug, and Cosmetics Act; monitor S. 2003, the FDA Cosmetic Safety and Modernization Act; educate on FDA regulation and safety in the cosmetics industry.
Client expense: Not reported · Firm income: $90,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
H.R. 575, Cosmetic Modernization Amendments of 2017; S. 1113, Personal Care Products Safety Act; S. 2003, FDA Cosmetic Safety and Modernization Act; Issues related to sunscreen regulations
Client expense: $480,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)
2018 · third_quarter · Health Issues
Cosmetic safety legislation including: H.R.575, Cosmetic Modernization Amendments of 2017 and S.1113, Personal Care Product Safety Act. H.R.6 SUPPORT for Patients and Communities Act H.R.5228 SCREEN Act H.R. 5752 Stop Illicit Drug Importation Act of 2018 S. 2680 Opioid Crisis Response Act of 2018
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
- S. 469/H.R. 1245, "Affordable and Safe Prescription Drug Importation Act", regarding all provisions. - S. 771/H.R. 1776, "Improving Access To Affordable Prescription Drugs Act", regarding all provisions. - H.R. 575, "Cosmetic Modernization Amendments of 2017", regarding all provisions. - H.R. 1271, "DXM Abuse Prevention Act of 2017", regarding all provisions. - S. 404/H.R. 1736, "To amend the Federal Food, Drug, and Cosmetic Act to improve the process for inspections of device establishments and for granting export certifications.", regarding all provisions. - Issues regarding drug pricing. - Issues related to diagnostic reform. - S 260/SJ Res 17/HR 849, Protecting Seniors' Access to Medicare Act of 2017, regarding all provisions - S 251/SJ Res 16, Protecting Medicare from Executive Action Act of 2017, regarding all provisions - S 204/HR 878, Right to Try Act of 2017, regarding all provisions - HR 2026, Pharmaceutical Information Exchange Act, regarding all provisions - HR 1703, Medical Product Communications Act of 2017, regarding all provisions - Issues related to VA procurement of medical devices - HR 2474, Medical Product Review Harmonization Act, regarding all provisions - HR 2144, Risk Based Classification of Accessories Act - Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects - S.1113, "Personal Care Products Safety Act", regarding all provisions - HR 2790, "Humane Cosmetics Act", regarding all provisions - HR 3271, "Protecting Access to Diabetes Supplies Act", regarding all provisions - Issues regarding medical device repeal - Issues regarding NIH Funding - HR 2164, "Medical Device Safety Act", regarding all provisions - Issues related to 340B - Issues related to HIV vaccines - S. 2852, "Pandemic & All Hazards Preparedness and Advancing Innovations Act of 2018", regarding all provisions. - Issues related to reauthorization of the Pandemic All-Hazards Preparedness Act programs. (House version) - HR 5492, "MOTHER Act of 2018", regarding all provisions. - Issues related to access to essential surgery - Issues related to contact lens safety - HR 6, "SUPPORT for Patients and Communities Act", regarding all provisions. - S. 2315, "Over-the-Counter Drug Safety, Innovation, and Reform Act", regarding all provisions. - HR 5333 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", regarding all provisions. - Issues related to antimicrobial resistance - Issues related to regulations on medication product packaging - H.R. 6294, " Re-Valuing Anti-Microbial Products Act of 2018", regarding all provisions
Client expense: $1,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA), White House Office
2018 · third_quarter · Health Issues
Legislation and regulations affecting medical devices, pharmaceuticals, cosmetics and other consumer products. Implementation of the 21st Century Cures Act (P.L.114-255). S.1113, Personal Care Products Safety Act. S.2003, FDA Cosmetic Safety and Modernization Act. S.2315, Over-the-Counter Drug Safety, Innovation, and Reform Act. H.R.5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018. S.2680, Opioid Crisis Response Act of 2018. H.R.6, SUPPORT for Patients and Communities Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
Legislation relating to chemical safety, cosmetic ingredients safety, and disclosure of fragrance ingredients in consumer products S. 1113 (Personal Care Products Safety Act), all provisions S. 2003 (FDA Cosmetic Safety and Modernization Act), all provisions H.R.575 (Cosmetic Modernization Amendments of 2017), all provisions H.R. 4964 (Children's Product Warning Label Act of 2018), all provisions H.R. 6903 (Safe Cosmetics and Personal Care Products Act of 2018), all provisions Formation of Congressional Fragrance Caucus
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Consumer Issues/Safety/Products
Legislation relating to Cosmetics Reform (chemical safety, cosmetic ingredient safety, and disclosure of fragrance ingredients in consumer products). HR 575; S 1113; S 2003; HR 4964; HR 6903, all provisions. Formation of Congressional Fragrance Caucus.
Client expense: $80,000 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Chemicals/Chemical Industry
H.R. 2, Agriculture Improvement Act of 2018; H.R. 5, Regulatory Accountability Act of 2017; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 21, Midnight Rules Relief Act; H.R. 26, Regulations from the Executive in Need of Scrutiny (REINS) Act; H.R. 33 Small Business Regulatory Flexibility Improvements Act of 2017; H.R. 45, Regulatory Accountability Act of 2017; H.R. 1029, Pesticide Registration Improvement Extension Act of 2017; H.R. 1430, Honest and Open New EPA Science Treatment (HONEST) Act of 2017; H.R. 1431, EPA Science Advisory Board Reform Act of 2017; H.R. 2811, Foreign Agents Registration Modernization and Enforcement Act; H.R. 3268, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018; H.R. 3381, Child Poverty Reduction Act 2017; H.R. 4170, Disclosing Foreign Influence Act; H.R. 4460, Disaster Recovery Reform Act; H.R. 4667, Making further supplemental appropriations for the FY ending 9/30/18, for disaster assistance for Hurricanes Harvey, Irma, and Maria, and calendar year 2017 wildfires, and for other purposes; H.R. 5228, Stop Counterfeit Drugs by Regulation and Enhancing Enforcement Now (SCREEN)Act H.R. 5310, Municipal Infrastructure Savings and Transparency Act; H.R. 5752, Stop Illicit Drug Importation Act of 2018 H.R. 6022, Accurate Labels Act H. Res 71, Providing for consideration of the joint resolution (H.J. Res. 41) providing for congressional disapproval under chapter 8 of title 5, United States Code, of a rule submitted by the Securities and Exchange Commission relating to "Disclosure of Payments by Resource Extraction Issuers", and providing for consideration of the joint resolution (H.J. Res. 40) providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Social Security Administration relating to Implementation of the NICS Improvement Amendments Act of 2007; H. Res. 223; H. Res. 229; H. Res. 1082, Providing for the concurrence by the House in the Senate amendment to H.R. 302, with an amendment. (Sec. 1234 Natl. Public Infrastructure Predisaster Hazard Mitigation, and Sec. 1235 Addl. Mitigation Activities); S. 584, Small Business Regulatory Flexibility Improvements Act; S. 625 Foreign Agents Registration Modernization and Enforcement Act; S. 1113, Personal Care Products Safety Act; S. 1679, Foreign Agent Lobbying Transparency Enforcement Act; S. 1794, HONEST Act; S. 1866, Hurricanes Harvey, Irma, and Maria Education Relief Act of 2017; S. 2039, Disclosing Foreign Influence Act; S. 2482, Foreign Agents Registration Amendments Act of 2018; S. 2680, Opioid Crisis Response Act of 2018; S. 3019, Accurate Labels Act; S. 3042, Agriculture Improvement Act of 2018; S. 3041, Disaster Recovery Reform Act of 2018; S. 3296, Sustainable Chemistry Research and Development Act of 2018; S. 3382, PFAS Detection Act of 2018; S. 3508, Save Our Seas Act 2018; S. 3551, SOFFA; S. Res. 301; S. Resolution Establishing the congressional budget; FY 2018 Appropriations of Department of Interior; FY 2018 Appropriations of Environmental Protection Agency; FY 2018 Appropriations Financial Services and General Government FY 2018 Appropriations of Transportation, Housing and Urban Development, and Related Agencies; FY 2018 Appropriations of Commerce, Justice, Science and Related Agencies; FY 2018 Appropriations of Department of Labor, Health and Human Services; FY 2019 Appropriations of Department of the Interior, environment, and related agencies; FY 2019 Appropriations of Department of Labor, Health and Human Services; Alternative Fuel Tax Assessment; Antimicrobials; Bisphenol-A; Building and Construction water infrastructure; Chemical Assessment; Chemical Safety Board; Chemistry Caucus; Chlorinated Paraffins; Chlorine; CPSC, including Phthalates, Flame Retardants, Nominations, and CHAP; Design for the Environment; Energy Recovery; EPA Nomination; Flame Retardants; Fluorotechnology including PFOA/PFOS/PFAS Formaldehyde; Hexavalent Chromium; Integrated Risk Information System; International Agency for Research of Cancer, including Report on Carcinogens Labeling and Packaging, including GMOs; Lautenberg Chemical Safety Act Implementation (LCSA) and regulations; Microbeads; Microplastics; Nanotechnology; NIOSH studies; OSHA Letters of Interpretation (Chemical Concentrations, Process Safety, RAGAGEP); Permitting Reform; Phthalates; Plastics; Rare Earths; Risk Assessment Improvements; Science Advisory Board; Sustainability including report on innovation and Research and Development Styrene; T-TIP, MTB and Trade Promotion Authority; Titanium Dioxide
Client expense: $2,250,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Energy, Dept of, Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Office of Management & Budget (OMB), Pipeline & Hazardous Materials Safety Administration, SENATE, Surface Transportation Board (STB), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2018 · third_quarter · Consumer Issues/Safety/Products
FDA regulation of cosmetics and Consumer Product Safety issues. Monitor data breach notification, cyber security and digital privacy proposals. S. 1113 - Personal Care Products Safety Act. S. 2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR)